Comparative Pharmacology
Head-to-head clinical analysis: BUSULFEX versus CISPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFEX versus CISPLATIN.
BUSULFEX vs CISPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death.
Platinum-based alkylating-like agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Busulfan 0.8 mg/kg IV every 6 hours for 4 days (total 16 doses) or 3.2 mg/kg IV once daily for 4 days, based on ideal body weight or actual body weight (whichever is lower).
50-100 mg/m² IV every 3-4 weeks; or 20 mg/m² IV daily for 5 days every 3-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range: 1.5-4.0 hours) in adults. In children, half-life is shorter (~1.4 hours). Clinically, this supports high-dose, fractionated dosing regimens (e.g., every 6 hours) to maintain therapeutic levels.
Clinical Note
moderateCisplatin + Digoxin
"Cisplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCisplatin + Digitoxin
"Cisplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCisplatin + Deslanoside
"Cisplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCisplatin + Acetyldigitoxin
"Cisplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is 20-30 hours (range 10-40 hours) in patients with normal renal function. This prolonged half-life is due to slow release of platinum from tissue binding and is clinically relevant for cumulative nephrotoxicity and ototoxicity.
Primarily hepatic metabolism via conjugation with glutathione, followed by renal excretion of metabolites. Less than 2% of the parent drug is excreted unchanged in urine. Fecal excretion is negligible.
Renal excretion accounts for 70-90% of cisplatin elimination, with approximately 20-50% excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Category C
Category D/X
Alkylating Agent
Alkylating Agent